The European Patent Office (EPO) has decided that the European patent on mutations in breast and ovarian cancer susceptibility (EP 705903) is to be maintained in amended form.
Related Articles
Senza categoria
The people’s pharmacologist
Editorial
Fake drugs pose a threat to Europe’s cancer patients
Drug Watch